Drug Trial News

RSS

Researchers explore optimal induction therapies for managing blood cancer

There have been significant scientific advances in the field of blood cancers, and leading experts continue to gain a better understanding of how certain diseases progress in order to discover new treatment options and provide patients with the best care.

7 Dec 2009

VELCADE based regimens are cost-effective for payers and patients, finds study

Millennium: The Takeda Oncology Company today announced that two studies presented at the 51st American Society of Hematology (ASH) Annual Meeting found that VELCADE based regimens are more cost-effective for payers and reduced out-of-pocket costs for patients than other commonly used multiple myeloma treatments.

7 Dec 2009

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Allos Therapeutics, Inc. today reported new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

7 Dec 2009

Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris

Alexion Pharmaceuticals, Inc. today announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris® (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH).

7 Dec 2009

Amgen announces results from three studies on the safety and efficacy of Nplate

Amgen Inc. today announced results from three studies on the safety and efficacy of Nplate® (romiplostim) in adult patients with myelodysplastic syndromes (MDS).

7 Dec 2009

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

Onyx Pharmaceuticals, Inc. today announced updated safety data from the pivotal Phase 2b 003-A1 study, known as the 003 trial, demonstrating that carfilzomib is well-tolerated in heavily pre-treated relapsed and refractory multiple myeloma patients.

7 Dec 2009

ImmunoGen reports encouraging clinical data of IMGN901

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients whose disease had progressed on multiple prior treatment regimens.

6 Dec 2009

Positive final data from Phase 2 study of ISTODAX presented

Gloucester Pharmaceuticals announced today the presentation of positive final data from a Phase 2 study of ISTODAX® (romidepsin) in peripheral T-cell lymphoma (PTCL) conducted by the National Cancer Institute (NCI) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

6 Dec 2009

Dabigatran etexilate offers effective therapy to prevent recurrent VTE

Results from the landmark RE-COVER(TM) study were presented today at the American Society of Hematology Annual Meeting and published online in the New England Journal of Medicine.

6 Dec 2009

Bortezomib can improve control of GVHD and immune system recovery

A drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors, according to early clinical trial results to be presented by Dana-Farber Cancer Institute investigators at the American Society of Hematology's (ASH) annual meeting on Sunday, Dec. 6 (Abstract 48, Ernest N. Morial Convention Center, Room 243-245, 5:45 pm CT).

6 Dec 2009

Oxygen Biotherapeutics commences enrollment in clinical trial of Oxycyte emulsion for TBI

Oxygen Biotherapeutics, Inc. today announced that the first patient has been enrolled in the company's Phase II-b, dose escalation, clinical trial in Switzerland for use of Oxycyte(TM) emulsion in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

5 Dec 2009

Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting

Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chronic myeloid leukemia (CML) have been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009.

4 Dec 2009

Results from Phase III pivotal study of FIRMAGON presented

Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurrence rate in a Phase III pivotal study of FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in prostate cancer patients during the first year of treatment.

4 Dec 2009

Pfizer to present study findings from its expanded breast cancer portfolio

Pfizer Oncology announced today that it will be presenting study findings evaluating several compounds including those from its newly expanded breast cancer portfolio following the recent acquisition of Wyeth, focusing on the needs of multiple breast cancer patient populations at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) being held December 9 – 13.

4 Dec 2009

Preclinical data of Curis' HSP 90 inhibitor published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that preclinical data related to CUDC-305, the company’s Heat Shock Protein (HSP) 90 inhibitor, was published online this week in Molecular Cancer Therapeutics.

4 Dec 2009

Allos Therapeutics, Idis collaborate in named patient program for FOLOTYN

Allos Therapeutics, Inc. today announced the execution of a collaborative agreement with Idis, a UK-based global company, to manage the named patient program for FOLOTYN™ (pralatrexate injection) outside of the United States. The U.S. Food and Drug Administration (FDA) has granted accelerated approval for FOLOTYN for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

4 Dec 2009

Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel

Results from a new study showed patients with type 2 diabetes who also had coronary artery disease (CAD) experienced greater antiplatelet activity with the investigational antiplatelet drug prasugrel compared to Plavix(R) (clopidogrel). Patients who received a 60 mg loading dose and 10 mg maintenance dose of prasugrel achieved significantly greater platelet inhibition compared with a 600 mg loading dose and 150 mg maintenance dose of Plavix.

4 Dec 2009

Genzyme announces reopening of enrollment in its Pompe disease ATAP program

Genzyme Corporation announced today that it will reopen enrollment in the Alglucosidase Alfa Temporary Access Program (ATAP), a program which provides access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme™ (alglucosidase alfa). Genzyme and the FDA have also agreed on a path toward approval of Lumizyme.

4 Dec 2009

Lightlake Therapeutics granted ethical approval for gene testing subjects in obesity treatment trial

After two decades of scientifically and medically proven success in their field, Lightlake Therapeutics' experts have been granted ethical approval to begin selecting and gene testing subjects for a trial of a simple, safe and effective treatment for what the World Health Organisation has described as a global epidemic of unhealthy eating and obesity.

3 Dec 2009

Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed the last patient visit in its Phase 2 FDG-PET clinical trial of VIA-2291.

3 Dec 2009